Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This is an ad hoc analysis of two phase II studies which compared the efficacy and safety of two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced gastric cancer. Materials and Methods Patients with advanced gastric adenocarcinoma who were untreated or had only received first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m2) or docetaxel (DFL; 75 mg/m2) on day 1, followed by a bolus of LV (20 mg/m2 days 1∼3) and a 24-hour infusion of 5-FU (1,000 mg/m2 days 1∼3) every 3 weeks. The primary endpoint was overall response rate (ORR) and the secondary endpoint included survival and toxicity. Results Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months, the progression free survival was 5.2 months (95% confidence interval [CI], 4.2∼6.5 months) for DFL and 3.3 months (95% CI, 1.3∼5.5 months) for PFL (p=0.17). The overall survival was also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2 ∼12.5 months] and 13.9 months [95% CI, 10.9∼19.2 months], respectively; p=0.37). The most frequent grade 3∼4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had different non-hematologic toxicities; specifically, grade ≥3 mucositis (5%) and diarrhea (3%) were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were common in PFL. Conclusion Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but different toxicity profiles. Prospective comparative studies are required to further clarify the role of taxanes in the treatment of advanced gastric cancer.
Abstract
Purpose This is an ad hoc analysis of two phase II studies which compared the efficacy and safety of two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced gastric cancer. Materials and Methods Patients with advanced gastric adenocarcinoma who were untreated or had only received first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m2) or docetaxel (DFL; 75 mg/m2) on day 1, followed by a bolus of LV (20 mg/m2 days 1∼3) and a 24-hour infusion of 5-FU (1,000 mg/m2 days 1∼3) every 3 weeks. The primary endpoint was overall response rate (ORR) and the secondary endpoint included survival and toxicity. Results Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months, the progression free survival was 5.2 months (95% confidence interval [CI], 4.2∼6.5 months) for DFL and 3.3 months (95% CI, 1.3∼5.5 months) for PFL (p=0.17). The overall survival was also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2 ∼12.5 months] and 13.9 months [95% CI, 10.9∼19.2 months], respectively; p=0.37). The most frequent grade 3∼4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had different non-hematologic toxicities; specifically, grade ≥3 mucositis (5%) and diarrhea (3%) were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were common in PFL. Conclusion Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but different toxicity profiles. Prospective comparative studies are required to further clarify the role of taxanes in the treatment of advanced gastric cancer.
참고문헌 (18)
- Lee JA, "FAM versus etoposide, adriamycin, and cisplatin: a random assignment trial in advanced gastric cancer", J Korean Cancer Assoc, 25, pp.461~467 (1993)
- Thuss-Patience PC, "Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study", J Clin Oncol, 23, pp.494~501 (2005)
- Kim YH, "Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma", Cancer, 85, pp.295~301 (1999)
- Murad AM, "Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen", Am J Clin Oncol, 22, pp.580~586 (1999)
- Bokemeyer C, "A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil", folinic acid in patients with advanced gastric cancer, 1997, pp.8, 396~399
- Jung JJ, "In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer", Genomics, 93, pp.52~61 (2009)
- Jeung HC, "A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer", Oncology, 70, pp.63~70 (2006)
- Im CK, "A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer", Cancer Chemother Pharmacol, 61, pp.315~321 (2008)
- Rigas JR, "Taxane-platinum combinations in advanced non-small cell lung cancer", a review. Oncologist, 9, pp.16~23 (2004)
- Esteban E, "Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy", Ann Oncol, 14, pp.1640~1647 (2003)
- Jones SE, "Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer", J Clin Oncol, 23, pp.5542~5551 (2005)
- Vasey PA, "Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma", J Natl Caner Inst, 96, pp.1682~1691 (2004)
- Imamura H, "Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer", ASCO Meeting Proc, 25, pp.S18~ (2007)
- Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial", Lancet Oncol, 9, pp.215~221 (2008)
- Van Cutsem E, "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~4997 (2006)
- Park SH, "Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil", Anticancer Drugs, 17, pp.225~229 (2006)
- Park SR, "Phase I", II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma, 2008, pp.98, 1305~1311
- Yeh KH, "Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer", Oncology, 69, pp.88~95 (2005)